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Analyzing bacterial extracellular vesicles in
human body ﬂuids by orthogonal biophysical
separation and biochemical characterization
Joeri Tulkens1,2, Olivier De Wever 1,2 and An Hendrix 1,2*
Gram-negative and Gram-positive bacteria release a variety of membrane vesicles through different formation routes.
Knowledge of the structure, molecular cargo and function of bacterial extracellular vesicles (BEVs) is primarily obtained
from bacteria cultured in laboratory conditions. BEVs in human body ﬂuids have been less thoroughly investigated most
probably due to the methodological challenges in separating BEVs from their matrix and host-derived eukaryotic
extracellular vesicles (EEVs) such as exosomes and microvesicles. Here, we present a step-by-step procedure to separate
and characterize BEVs from human body ﬂuids. BEVs are separated through the orthogonal implementation of
ultraﬁltration, size-exclusion chromatography (SEC) and density-gradient centrifugation. Size separates BEVs from
bacteria, ﬂagella and cell debris in stool; and blood cells, high density lipoproteins (HDLs) and soluble proteins in blood.
Density separates BEVs from ﬁbers, protein aggregates and EEVs in stool; and low-density lipoproteins (LDLs), very-low-
density lipoproteins (VLDLs), chylomicrons, protein aggregates and EEVs in blood. The procedure is label free, maintains
the integrity of BEVs and ensures reproducibility through the use of automated liquid handlers. Post-separation BEVs are
characterized using orthogonal biochemical endotoxin and Toll-like receptor-based reporter assays in combination with
proteomics, electron microscopy and nanoparticle tracking analysis (NTA) to evaluate BEV quality, abundance, structure
and molecular cargo. Separation and characterization of BEVs from body ﬂuids can be done within 72 h, is compatible with
EEV analysis and can be readily adopted by researchers experienced in basic molecular biology and extracellular vesicle
analysis. We anticipate that this protocol will expand our knowledge on the biological heterogeneity, molecular cargo and
function of BEVs in human body ﬂuids and steer the development of laboratory research tools and clinical diagnostic kits.
Introduction
The secretion of proteins, nucleotides, lipids and other factors is a vital process in all living organisms
and is important for inter-kingdom interactions in health and disease1. The human intestinal tract
is constantly exposed to environmental antigens and vast quantities of commensal bacteria that
generally live in a symbiotic and mutually beneﬁcial relationship with their host. Accumulating
evidence shows that these interactions inﬂuence, at least in part, cancer, mental health, and cardio-
vascular and immune disorders2–5.
Short- and long-distance interaction between bacteria and the host occurs through direct contacts
and secreted products, such as (quorum-sensing) peptides, proteins, nucleic acids, lipoglycans and
membrane vesicles, also termed bacterial extracellular vesicles6. The ﬁrst evidence of extracellular
vesicle secretion by Gram-negative bacteria was obtained in the 1960s (refs. 7,8). The existence of
extracellular vesicles produced by Gram-positive bacteria was reported 30 years later9. Gram-negative
bacteria have two main routes of vesicle formation: blebbing of the outer membrane of the bacterial
envelope, forming outer membrane vesicles, or explosive cell lysis, generating outer–inner membrane
vesicles or explosive outer membrane vesicles. Bubbling of Gram-positive bacteria gives rise to
cytoplasmic membrane vesicles7. Independent of their biogenesis pathways, all membrane vesicles are
hereafter referred to as BEVs. BEVs released by Gram-negative bacteria are characterized by an
interior leaﬂet of phospholipids and an exterior leaﬂet of lipopolysaccharide (LPS), which activates
immune cells through Toll-like receptor (TLR) 4 (ref. 7). Gram-positive bacteria, and thus also their
BEVs, show surface lipoteichoic acid (LTA), which activates immune cells through TLR2 (ref. 10). The
variety in membrane envelope structure and biogenesis route results in the production of BEVs of
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various size, density and molecular cargo. In close parallel to EEVs, which include exosomes,
microvesicles and apoptotic bodies, BEVs are heterogeneous. The production and relative distribution
of BEV subtypes depend on the bacterial species and their physiological state11. Most of the
knowledge of BEV biogenesis, structure, molecular cargo and function is obtained from extensive
studies using bacteria cultured in laboratory conditions.
Analysis of human body ﬂuids has become one of the most promising approaches to discovering
biomarkers and revealing pathophysiological mechanisms, but is inherently challenging because of its
complexity. EEVs have been identiﬁed in many human body ﬂuids, including blood. Because EEVs
contain a sample of the cellular content, including proteins, nucleic acids and other analytes, EEVs
have been increasingly explored in a quest to enable easy and efﬁcient diagnosis and monitoring
of disease progression and therapy response—with potential applications in cancer diagnostics
being one example of imminent use12. Although the colonization of speciﬁc body sites in contact with
the external environment (such as the gastrointestinal tract) by bacteria is universally accepted13, the
study of BEVs in body ﬂuids, including blood, is a new concept. BEVs have been observed in
cerebrospinal ﬂuid and blood plasma from patients with clinically severe bacterial infections14,15, in
stool from healthy donors16 and in gastric biopsy specimens from Helicobacter pylori–infected
patients17. The identiﬁcation of the biological heterogeneity, molecular cargo and function of BEVs
that prevail in each particular body ﬂuid, however, requires protocol development to allow repro-
ducible analysis of BEVs. We have recently developed a protocol that integrates orthogonal bio-
physical separation with biochemical characterization to analyze BEVs in human blood plasma and
stool. Using this protocol, we succeeded in identifying BEVs in blood plasma of non-septic patients,
with concentrations ranging from 105 to 106 BEVs per ml of blood plasma. Importantly, we showed
that BEVs from blood plasma are able to induce immune activation and that the systemic presence of
BEVs associates with increased permeability of the intestinal epithelial barrier6. To steer reproducible
analysis of BEVs in human body ﬂuids, which is required to further unravel the biological properties
and explore the clinical potential of these speciﬁc entities, we here present a step-by-step procedure to
separate and characterize BEVs. We hope that our protocol will circumvent the problem that lack of
awareness of the co-separation of BEVs with EEVs, lipoproteins, soluble proteins, ﬂagella and protein
aggregates may lead to wrong conclusions about the molecular cargo and functions of BEVs18–21.
Overview of the protocol
Orthogonal biophysical separation of BEVs
A plethora of methods have become available to separate extracellular vesicles from different
bioﬂuids, including human body ﬂuids. The majority of these methods use biophysical or
biochemical characteristics of extracellular vesicles, such as size, density and surface molecules. The
speciﬁcity of the separation method for extracellular vesicles is determined by the complexity of
the starting material and thus the overlap of biophysical and biochemical characteristics of extra-
cellular vesicles with other biological components that prevail in the particular body ﬂuid. Because
different body ﬂuids have a highly variable compositions, each protocol to recover extracellular
vesicles from body ﬂuids may require speciﬁc protocol steps. The size and density distributions
of diverse biological components of blood and stool are shown in Fig. 1. In blood, BEVs overlap, at
least in part, in size (size range ~50–250 nm) with EEVs, protein aggregates, VLDLs, LDLs and
chylomicrons. In stool, BEVs overlap, at least in part, in size with EEVs and protein aggregates, and
partially overlap with pili and ﬂagellar fragments in density. To separate BEVs with high speciﬁcity
from blood plasma and stool, we developed a protocol that orthogonally implements size-based and
density-based methods with some body ﬂuid–speciﬁc modiﬁcations. The workﬂow of the orthogonal
biophysical separation of BEVs from blood plasma and stool is outlined in Fig. 2 and is described
further below.
After collection and resuspension of the stool sample in endotoxin-free PBS, a crude extract is
prepared by ultraﬁltration, which allows cell debris, ﬁbers, pili and ﬂagella >0.22 µm to be adequately
removed. The crude extract is mixed with a high-density iodixanol solution and overlaid with
step gradients of low-density iodixanol solutions. Bottom-up density-gradient centrifugation allows
further separation of BEVs from other biological components present in the crude extract, including
low-molecular-weight proteins and small ﬁbers that are denser and/or do not ﬂoat and thus remain in
the bottom fractions of the gradient. Next, BEVs are retrieved from density fractions by SEC, which
removes iodixanol—which may interfere with biochemical characterization—and remnants of other
biological components such as ﬂagellar fragments. Iodixanol (OptiPrep) is the most frequently used
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density-gradient medium for BEV separation from bacterial cell cultures because it is iso-osmotic at
useful concentrations, preventing damage of sensitive membranous structures22.
For blood samples, after collection, platelet-depleted plasma is prepared and a crude extract is
obtained by SEC, which allows HDLs and low-molecular-weight proteins to be depleted. The crude
extract is layered on top of the density gradient (top-down density-gradient centrifugation) to further
separate BEVs from other biological components present in the crude extract, including EEVs,
VLDLs, LDLs and chylomicrons that are less dense and thus remain in the top fractions of the density
gradient. BEVs are retrieved from density fractions by SEC.
Orthogonal biochemical and functional characterization of BEVs
Characterization of BEV preparations by multiple complementary methods is important to evaluating
the likelihood that identiﬁed molecular cargo and functions are associated with BEVs and not
other biological components. In addition, each method contributes speciﬁc insights into biological
heterogeneity, abundance, structure, molecular cargo and function. In this protocol, post-separation
BEVs are characterized using endotoxin and TLR-based reporter assays in combination with pro-
teomics, electron microscopy and NTA (Fig. 3). The implementation of a biochemical endotoxin
(Limulus amebocyte lysate (LAL)) and TLR reporter assays in combination with NTA allows the total
number of BEVs as well as the relative abundance of Gram-positive (LTA assessed by TLR2 assay)
versus Gram-negative BEVs (LPS assessed by TLR4 and LAL assays) to be quantiﬁed. Mass
spectrometry–based proteomics, western blot analysis and ELISA assays identify outer- and inner-
membrane proteins and cytosolic proteins associated with BEV, but also non-BEV components, such
as lipoprotein-associated apoA-I and EEV-associated proteins. Human peripheral blood mono-
nuclear cells (PBMCs) are used as an ex vivo test model to investigate the immune modulatory impact
of BEVs.
Applications
We demonstrated in our previous publication for the ﬁrst time that BEVs reside in blood; that their
numbers associate with increased permeability of the intestinal epithelial barrier in HIV,
Chylomicrons
EEVs
BEVs
HDLs
LDLs
VLDLs, IDLs
>1 μm 
~20 nm 
~10 nm 
LPS, proteins,...
Un
di
ge
st
ed
 fo
od
, b
ac
te
ria
, b
lo
od
ce
lls
, p
la
te
le
ts
, l
ar
ge
 fi
be
rs
,..
.
D
en
si
ty
Size
Blood plasma
Stool
Crude
extract
Protein aggregates, fibers, pili, flagella
<
1.
08
3 
g/
m
l
>
1.
11
1 
g/
m
l
Fig. 1 | Schematic size and density indication of BEVs compared to contaminants present in stool and/or blood
plasma. The size and density ranges of components obtained by orthogonal separation of stool and blood plasma.
Note that only the hotspot location for each biological component is visualized. IDL, intermediate-density lipoprotein.
Image adapted with permission from BMJ Publishing Group Limited. Gut, Tulkens et al.6, 10.1136/gutjnl-2018-
317726, © 2018.
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inﬂammatory bowel disease (IBD) and chemotherapy-treated cancer patients; and that they harbor
the capacity to activate PBMCs in an ex vivo assay6. Importantly, we showed that orthogonal
biophysical separation is necessary and sufﬁcient to characterize BEVs, as evidenced by the lack of
association between other LPS products, such as LPS neutralized by lipoproteins and endotoxin core
antibodies, and the permeability of the intestinal epithelial barrier6.
The protocol can be adapted for an array of body ﬂuids from human or any other species, given
their similar matrix complexity. BEV separation from other body ﬂuids may, however, require
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Fig. 2 | Illustrative overview of the BEV separation protocol. a,b, Separation of BEVs from body ﬂuids such as stool samples (a), shown in the
Procedure, and blood plasma (b), detailed in Box 2, by orthogonal biophysical methods. a, After collection and preparation of the stool sample, a crude
extract is prepared by ultraﬁltration. BEVs are separated and recovered from this extract using the combination of a bottom-up density gradient and
SEC. b, After collection of the blood sample, platelet-depleted plasma is prepared and a crude extract is obtained by SEC. BEVs are separated and
recovered from this extract using the combination of a top-down density gradient and SEC. The expected BEV concentration is given per gram of stool
sample (with a BSS category of 3 or 4) or milliliter of blood plasma. Steps requiring sample volume reduction are indicated with an asterisk. In addition,
we present alongside a color coded scale to show BEV enrichment of stool and blood plasma relative to body ﬂuid–speciﬁc contaminants.
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inclusion or optimization of speciﬁc protocol steps. To allocate biomarkers and functions to BEVs,
lower- and higher-density fractions or smaller-size fractions can be included in control experiments.
Furthermore, results from low-biomass samples are prone to misinterpretation due to the potential
presence of contaminating molecules derived from laboratory reagents and environments. Thus, the
possibility of contaminants demands careful evaluation and appropriate controls23. In parallel to BEV
analysis, the protocol supports the analysis of EEVs that reside in the studied body ﬂuid, because
density-gradient centrifugation from crude extracts separates EEVs (1.083–1.111 g/ml) from higher-
density BEVs (1.133–1.201 g/ml) with high speciﬁcity.
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This protocol yields integrated information on the size, buoyant density, quantity, relative
abundance of Gram-negative and Gram-positive BEVs, ultrastructure, molecular cargo and function
of BEVs. By combining these characteristics, BEV subsets can be mapped within stool and blood
plasma, and by extension other body ﬂuids, which will undoubtedly expand our knowledge of the
biological heterogeneity and function of BEVs in body ﬂuids. Ensuring reproducibility through the
implementation of automated liquid handlers allows associations of the quantity and molecular cargo
of BEVs with multiple disease conditions to be investigated, which will inherently support the clinical
application of BEVs as biomarkers of disease. Last but not least, we envision that this protocol can
serve as a reference in the further development and optimization of methods for separating and
characterizing BEVs. A unique advantage of the protocol is the high speciﬁcity toward BEVs, which
allows BEV characteristics such as zeta potential, surface molecules, buoyant density and size to be
unraveled and can be exploited for the development of laboratory research tools and clinical
diagnostic kits.
Taken together, we anticipate that the protocol will stimulate research on BEVs in body ﬂuids,
an exciting research domain that yet remains largely unexplored. The applications and target
audience are broad, including research ﬁelds covering biomarkers, liquid biopsies, microbiome,
extracellular vesicles, membrane vesicles, disease areas characterized by increased intestinal barrier
permeability (such as HIV, IBD, cancer) and technical ﬁelds focusing on separation of macro-
molecular biomolecules.
Comparison with other methods
A plethora of separation methods have become available to retrieve extracellular vesicles from
different bioﬂuids, including body ﬂuids. The majority of these methods use biophysical or bio-
chemical characteristics of extracellular vesicles, such as size (differential ultracentrifugation,
asymmetric-ﬂow ﬁeld-ﬂow fractionation, SEC, ultraﬁltration), buoyant density (density-gradient
centrifugation) or surface molecules (primarily proteins; immune afﬁnity capture)21. The working
mechanisms, advantages and limitations of these methods have been recently reviewed19. The
speciﬁcity of the separation method for extracellular vesicles is determined by the complexity of the
starting material and the overlap of biophysical and biochemical characteristics with other bioﬂuid
components. Indeed, biophysical characteristics are not unique to extracellular vesicles. Protein
aggregates and lipoproteins, among other biological components, have a size or density range similar
to that of extracellular vesicles. Traditional one-step physical-based methods have been successfully
implemented to separate extracellular vesicles from cell culture supernatant with high speciﬁcity18 but
are not sufﬁcient to separate extracellular vesicles from body ﬂuids6,19. Immune-afﬁnity capture
exploits the biochemical surface composition to separate extracellular vesicles with a high speciﬁcity
but requires knowledge of surface antigens (which is not yet available for BEVs residing in body
ﬂuids), inherently selecting for subpopulations and interfering with functional analysis because of
antibody binding.
Fig. 3 | Possibilities for characterization of BEVs in relation to their concentration. Several general and functional
techniques for BEV characterization are shown at the top (NTA (Step 29A), western blot analysis (Step 29C) and
PBMC stimulation (Step 29F)), whereas orthogonal approaches to characterizing different subtypes of BEVs are
proposed in the bottom half (immunoelectron microscopy (Step 29B), LAL assay (Step 29D), TLR2/4 reporter
assays (Step 29E) and proteomic analysis (Step 29G)). BEV subtypes include OMVs, OIMVs and CMVs. The BEV
concentration required to perform a particular technique is represented as a function of all the approaches (see
graph in the middle of the ﬁgure). The presence of certain proteins is revealed by western blot analysis and a BEV
size distribution proﬁle is obtained by NTA. After PBMC stimulation, a wide array of chemokines and cytokines are
released, in contrast to non-stimulated PBMCs. Within the detection range of the PAMP characterization assays, a
linear relationship exists between LPS (EU/ml), TLR2 or TLR4 activity (OD 630 nm) and BEV concentration (data
points of three technical replicates and error bars (s.d.) are represented; LAL: Pearson’s r = 0.9994; TLR2: Pearson’s
r = 0.9145; TLR4: Pearson’s r = 0.9814). Immuno-electron microscopy is performed using anti-LPS antibodies. The
results shown for the techniques marked with an asterisk were obtained by using stool-derived BEVs; the others
were obtained by using EcN BEVs. Scale bars, 200 nm. ENA-78, epithelial neutrophil activating protein 78; EU,
endotoxin units; GRO-α, growth-regulated alpha protein; I-309, T lymphocyte–secreted protein I-309; IL, interleukin;
MCP, monocyte chemoattractant protein; MIP, macrophage inﬂammatory protein; OD, optical density; Sus, starch
utilization system protein; TRAIL, TNF-related apoptosis-inducing ligand. In this study, collection of stool samples
was approved by the Ethical Committee of Ghent University Hospital and performed in accordance with relevant
guidelines. The patients provided informed written consent. Image adapted with permission from BMJ Publishing
Group Limited. Gut, Tulkens et al.6, 10.1136/gutjnl-2018-317726, © 2018.
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Absolute BEV counting could be aided by appropriate reference materials and is most
informative for separation methods with high speciﬁcity, such as the orthogonal biophysical
separation presented in this protocol. As biological reference material, we propose trackable
recombinant extracellular vesicles, such as those developed by our group24. Alternative characteri-
zation methods to those presented in this protocol can be implemented, as long as these methods
ensure the combined assessment of single BEVs using two complementary methods and the detection
of both BEV-associated proteins and non-BEV-associated proteins, in compliance with the
MISEV2018 guidelines25.
Limitations
The sequential implementation of a size-based method to reduce body ﬂuid complexity and a
density-based method is necessary and sufﬁcient to separate BEVs from other biological components
residing in body ﬂuids. However, no single protocol can be universally applied for the analysis of
different body ﬂuids as illustrated in this protocol for blood plasma and stool. The separation method
must be adapted on the basis of the complexity (i.e., sample volume and composition) of the body
ﬂuid of interest.
A second limitation of orthogonal biophysical separation is the need for two sequential separation
methods, including density-gradient centrifugation, which hampers high-throughput processing of
human body ﬂuids for BEV analysis. Density-gradient centrifugation is, however, critical to separate
BEVs with high speciﬁcity from other biological components of body ﬂuids, such as lipoproteins,
protein aggregates, ﬁbers and EEVs. A similar level of speciﬁcity cannot be achieved with other
separation methods available to date. Importantly, implementation of fully automated density-
gradient preparation and fraction collection renders density-gradient centrifugation highly repro-
ducible, operator independent, robust and less time consuming.
The stringency of the criteria used to select the size and density fractions will determine the
speciﬁcity and efﬁciency of BEV recovery from body ﬂuids. This protocol was developed to recover
BEVs with high speciﬁcity, which is needed to map the biochemical and biophysical characteristics of
BEVs. Rational criteria for the selection of these size and density fractions are determined in function
of (i) maximizing BEV recovery and (ii) minimizing the level of cross-contamination with other
biological components (e.g., co-isolation of EEVs). The required stringent collection of these fractions
will result in loss of some BEVs. The heterogeneity of BEV density, owing to differences in, for
example, environmental conditions, bacterial growth phase and species11,26–28, may thus result in the
exclusion of BEVs that have lower densities, overlapping with EEVs. While establishing the protocol,
we recommend that researchers evaluate all size and density fractions in order to identify the
fractions containing the BEVs of particular interest and then calculate their size and density. These
observations are driven by in vitro studies. Implementation of our protocol may reveal whether these
ﬂuctuations in size and density range are reﬂected in BEVs residing in human body ﬂuids.
Relevant issues, such as standardization of sample collection, handling and storage of human body
ﬂuids for the study of BEVs, have not been addressed. For blood plasma, we recommend following
the standard operating procedures provided in the MISEV2018 guidelines25. For stool samples, we
recommend following the standard operating procedures provided by the International Human
Microbiome Standards (IHMS) project29. Comparative studies of sample collection and storage are,
however, warranted to create reliable biorepositories for the study of BEVs in body ﬂuids.
Experimental design
Sample collection
A variety of experimental parameters are inherently associated with body ﬂuid collection, handling
and storage (e.g., type of container, time to storage, storage temperature and transport) and will
directly impact the recovery and integrity of BEVs. The IHMS project has developed standard
operating procedures for stool collection and handling for DNA analysis29. Several publications have
listed recommendations for blood collection and handling for the analysis of EEVs20,30,31. To date, the
effects of these experimental parameters on different classes of extracellular vesicles, including BEVs,
are unclear. In this protocol, we perform and transparently report on body ﬂuid collection, handling
and storage according to the current state of the art to ensure protocol reproducibility (Box 1;
refs. 20,21,25). Sterile endotoxin-free materials must be used for all steps. An overview of sample
collection is provided in Fig. 2.
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The choice between fresh and frozen body ﬂuids is determined by a laboratory’s accessibility to
fresh body ﬂuids and capacity for immediate orthogonal biophysical separation and biochemical
characterization. Sample collection, handling and storage must be performed identically for com-
parative studies of BEVs (Fig. 4). The total volume of blood plasma or mass of stool sample required
is determined by the number and type of downstream characterizations. Furthermore, because
numerous host and environmental factors are reported to inﬂuence the microbiome, hypothesis-
driven metadata collection—providing donor information on antibiotic (or other therapeutic)
interventions, dietary intake and a range of other markers of health—must be considered.
In the Procedure, we provide a protocol for collecting and analyzing stool samples as an example.
Stool samples are collected in sterile, wide-mouth containers, refrigerated (4 °C), kept in ice packs
during transport and delivered by the donor to the clinician within 24 h after defecation, in accor-
dance with the legal requirements of the country and the guidelines of the institution (Step 1).
General recommendations from laboratories routinely performing stool collection can be applied.
Stool consistency measurements using the Bristol Stool Scale (BSS) are performed to allow con-
founder analysis, because stool consistency inﬂuences bacterial species richness or community
composition32. The time interval between stool collection and preparation should be minimized, or
at least be kept constant, between samples to limit effects on the concentration and functional
activity of BEVs.
In Box 2, we then highlight the changes to the Procedure that are necessary in order to apply it
to the analysis of blood samples. Donor blood is drawn by venipuncture into sterile citrate tubes by
a trained physician or nurse, in accordance with the legal requirements of the country and
the guidelines of the institution (Box 2). General recommendations from laboratories routinely
performing blood collection can be applied. Plasma is usually the preferred source of EEVs because
additional vesicular structures are released during clot formation when preparing serum. At present,
citrate is the anticoagulant most commonly used to study EEVs, and the use of citrate blood collection
tubes has been recommended by the International Society on Thrombosis and Haemostasis30.
The time interval between blood collection and blood plasma preparation should be minimized, or
at least be kept constant between samples, to limit effects on the concentration and functional
activity of BEVs.
Sample preparation
An overview of sample preparation is provided in Fig. 2. We recommend that all steps be carried out
in a laminar ﬂow cabinet to avoid contaminations. Sterile, endotoxin-free materials must be used for
all steps.
Stool samples are resuspended in endotoxin-free PBS and depleted of large components, such
as bacteria, cell debris, dead leukocytes and undigested material, by implementing a two-step
centrifugation at 8,000g for 15 min at 4 °C (Steps 2–7). Because this centrifugation does not exclude
the presence of bacterial contamination in the prepared stool sample, we recommend continuing
directly to crude extract preparation (Steps 8–15).
Blood plasma must be processed to deplete platelets and blood cells by implementing a two-step
centrifugation at 2,500g for 15 min at room temperature (19 °C) (Box 2). Plasma depleted
from platelets can be divided into single-use aliquots to avoid freeze–thaw cycles and can be stored at
−80 °C. Freeze–thaw cycles and short-term storage of blood plasma may impact BEV concentration,
integrity and molecular composition because of cargo leakage.
Box 1 | Transparent reporting of BEV studies using EV-TRACK
Transparent reporting is a prerequisite for the successful interpretation and reproducibility of published
experiments. We strongly encourage researchers to add experimental parameters to the EV-TRACK
knowledgebase21. EV-TRACK is a free online toolset (http://evtrack.org) that centralizes EV biology and
methodology with the goal of stimulating authors, reviewers and editors to put experimental guidelines into
practice, enhancing the performance, characterization and reporting of BEV-related research. The EV-METRIC
represents a checklist with which to assess the completeness of reporting of the generic and method-speciﬁc
information necessary to interpret and reproduce an experiment. Currently, only 3.62% of all studies uploaded
into EV-TRACK are BEV related, with a mean EV-METRIC of 21.9%. The use of density-based separation is
reported in 29.0% of these studies, and in more than 17% of the BEV studies, no characterization of the
separated vesicles is performed.
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Orthogonal biophysical separation of BEVs
BEVs (~50–250 nm) are smaller than bacteria (~1 µm) and larger than HDLs (~10 nm), and small
and large low-molecular-weight proteins and lipids (<5 nm)19. Fibers and protein aggregates can be
present in a wide range of sizes (>1 nm; Fig. 1). According to these physical properties, we implement
size-based methods leading to a separation of BEVs from these components but resulting in co-
separation with LDLs, VLDLs, chylomicrons, protein aggregates and EEVs in blood plasma, and
small ﬁbers, low-molecular-weight proteins, protein aggregates and EEVs in stool (Fig. 2; Steps 8–15).
To increase the speciﬁcity toward BEVs, we sequentially exploit another intrinsic physical property
of extracellular vesicles, namely density. BEVs (1.133–1.201 g/ml) differ in buoyant density from
LDLs, VLDLs, chylomicrons (1.041–1.083 g/ml), protein aggregates, low-molecular-weight proteins
and ﬁbers (±1.4 g/ml) and EEVs (1.083–1.111 g/ml) (Fig. 1; ref. 19). Submitting the crude extract to
robot-assisted density-gradient centrifugation achieves a high speciﬁcity for BEVs while minimizing
co-separation of other biological components (Fig. 2; Steps 16–27).
Multiple size-based methods are available to prepare a crude extract from a body ﬂuid. A SEC
column packed with cross-linked Sepharose 2B beads is used to reduce viscosity of body ﬂuids prior
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Fig. 4 | Optimization of different steps of the orthogonal separation methods. a, BEV separation was performed on
three different biological replicates of stool samples stored for 24 h at RT or 4 °C (no freezing) and −20 °C or
−80 °C (freezing). The y axis represents the ﬁnal BEV concentration in stored stool samples as compared to BEVs
separated from the same stool sample immediately after collection. The body of the box plots represents the ﬁrst
and third quartiles of the distribution, and the median line. The whiskers comprise the minimum and maximum
values. In the case of storage without freezing, the ﬁnal BEV concentration is signiﬁcantly increased due to ex vivo
BEV production in non-freezing conditions (P = 0.0313, one-sample Wilcoxon signed-rank test). b, Determination of
the maximum stool concentration in PBS in order to avoid sample saturation and to maximize BEV recovery. For each
stool sample concentration (percentage (wt/vol) shown on the x axis (grams of stool sample/100 ml of PBS)), BEV
separation was performed on ﬁve different biological replicates. Individual data points and error bars (s.d.) are
represented. Sample saturation occurs from 10 g of stool/100 ml of PBS; from this concentration on, an increase in
the amount of stool sample no longer results in higher BEV concentrations. c, BEV purity is dependent on the
procedure used for BEV recovery in Step 28. A relative high amount of non-BEV structures (arrows) can be observed
by electron microscopy when recovering BEVs from density fractions with ultracentrifugation compared to SEC
(scale bars, 200 nm). In this study, collection of stool samples approved by the Ethical Committee of Ghent
University Hospital and performed in accordance with relevant guidelines. The patients provided informed written
consent. RT, room temperature.
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to BEV separation. SEC enables the separation of particles on the basis of their molecular size because
of their differential ability to percolate through pores of a given column matrix. In general, larger
particles are excluded from the pores and pass through more rapidly (elute ﬁrst from the column),
whereas smaller particles will migrate through these pores, prolonging their transit through the
matrix. The ability to separate particles of a given size range is determined by the pore size of the
Box 2 | Protocol modiﬁcation for BEV analysis from blood samples ● Timing 72 h
Procedure
Sample collection
1 Use a 21-gauge needle to collect venous blood samples into 3.2% (wt/vol) sodium citrate tubes. Use a BioDrop DUO spectrophotometer to
conﬁrm the absence of hemolysis by the lack of a spectrophotometric absorbance peak for free hemoglobin at 414 nm.
! CAUTION Experiments using human samples must conform to local and national regulations. In this study, collection of blood samples was
done according to Ethical Committee of Ghent University Hospital approvals EC/2014/0655 and EC/2017/0882 and in accordance with the
relevant guidelines. Informed consent must be obtained when using patient plasma.
Sample preparation
2 Within 120 min after collection, centrifuge blood at 2,500g for 15 min at room temperature, resulting in plasma. Transfer the plasma to a new
sterile plastic tube.
c CRITICAL STEP We recommend preparing plasma because serum contains additional vesicles that are released during in vitro clot
formation44.
3 Centrifuge the plasma again at 2,500g for 15 min at 19 °C to obtain platelet-depleted plasma. Transfer the platelet-depleted plasma to a new
sterile plastic tube. To ensure the depletion of platelets in plasma, we use the hematology analyzer. This device provides a complete blood count
on small (50 µl) sample volumes with a high level of accuracy and sensitivity.
j PAUSE POINT Plasma can be stored at −80 °C for several months.
Crude extract preparation
4 Perform Step 28A of the Procedure on 2 ml of plasma and collect SEC fractions 4–6. Make use of endotoxin-free PBS supplemented with
0.32% (wt/vol) trisodium citrate dihydrate. SEC fractions >6 are not collected because of the presence of substantial amounts of contaminating
proteins.
5 Concentrate SEC fractions 4–6 to a 1-ml sample with a 10-kDa centrifugal ﬁlter.
BEV separation
6 Perform Step 16 of the Procedure.
7 Perform Step 17 of the Procedure. Replace gradient buffer A with endotoxin-free PBS.
c CRITICAL STEP Because the BEV concentration in blood samples is low, and the ﬁnal detection techniques are very sensitive, it is of utmost
importance to avoid any kind of bacterial or endotoxin contamination. Therefore, we replace gradient buffers A and B with endotoxin-free PBS to
exclude potential contamination caused by these reagents.
8 Perform Step 18 of the Procedure. Replace the gradient buffer B with endotoxin-free PBS. In addition, also prepare a 5% (wt/vol) iodixanol
solution by mixing 0.5 ml of the working solution with 4.5 ml of endotoxin-free PBS.
9 Prepare a density gradient similar to those in Step 20 of the Procedure, but use a slightly modiﬁed density-gradient structure, as follows:
carefully transfer 4 ml of the 40% (wt/vol) iodixanol solution to the bottom of a thin-walled polypropylene centrifugation tube. Slowly tilt
the tube to 70° and carefully transfer (drop by drop) 4 ml of the 20% (wt/vol) iodixanol solution onto the surface of the liquid (close to the
opening of the tube). Carefully transfer (drop by drop) 4 ml of the 10% (wt/vol) iodixanol solution onto the surface of the liquid (close to
the opening of the tube). Carefully transfer (drop by drop) 3.5 ml of the 5% (wt/vol) iodixanol solution onto the surface of the liquid (close to
the opening of the tube). Carefully transfer (drop by drop) 1 ml of sample (i.e., the concentrated SEC fractions from step 5 of this box) onto the
surface of the liquid (close to the opening of the tube).
10 Perform Steps 21–26 of the Procedure.
11 Perform Step 27 of the Procedure. Pool density fractions 12 and 13 (as these contain the BEVs) and immediately place them on ice. EEVs are
mainly enriched in lower-density fractions (8, 9 and 10).
BEV recovery
12 Perform Step 28A of the Procedure.
13 Concentrate the collected SEC fractions to 100 µl using a 10-kDa centrifugal ﬁlter.
j PAUSE POINT The BEVs can be used immediately or stored at −80 °C for up to several months.
BEV characterization
14 Starting from 2 ml of plasma, the following procedures for BEV characterization can be used: TLR2/TLR4 activity measurement (Step 29E of the
Procedure) and PBMC stimulation experiments (Step 29F of the Procedure). Perform these techniques on undiluted BEV samples. LPS activity
measurements (Step 29D of the Procedure) can be performed on 1:5 diluted BEV samples (dilution in endotoxin-free PBS). Also immuno-EM
can be performed (Step 29B of the Procedure) using, for example, anti-LPS antibodies. In this case, incubation of the grids in blocking solution
(1% BSA in endotoxin-free PBS) is critical in order to reduce aspeciﬁc binding. The blocking efﬁciency must be controlled by performing the
labeling procedure in the absence of primary antibody. Western blot analysis can be performed to detect EEV (markers: Flotillin-1, CD9 and
ALIX) and lipoprotein contamination (HDL marker: apoA-I).
As with BEV separation from stool samples, we recommend performing a blank BEV separation starting from 2 ml of endotoxin-free PBS and
performing the characterization techniques (described in step 14 of this box) on the ﬁnal sample. This sample serves as a protocol control and
will allow detection of any contamination.
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exclusion matrix, for example, Sepharose 2B has a pore size of ≈60 nm (ref. 20). As for other size-
based techniques, SEC fractions containing BEVs should be empirically identiﬁed for each body
ﬂuid33,34. Multiple SEC fractions containing BEVs can be combined to increase recovery efﬁciency.
The input sample volume for SEC is restricted, rendering the method less suitable for large-volume
body ﬂuids such as prepared stool. For blood plasma, SEC returns a crude extract, depleted of HDLs
and small low-molecular-weight proteins. Ultraﬁltration using 0.22-μm ﬁlters returns a crude extract
from stool, depleted of ﬁbers, large protein aggregates and undigested food. The crude extracts are
further concentrated by centrifugal ﬁlters with cellulose membrane and 10-kDa pore size35. Both
crude extracts are characterized by a high efﬁciency (i.e., minimal loss of BEVs) but low speciﬁcity for
BEVs. Crude extracts can be frozen at −80 °C until further use.
Crude extracts obtained from stool and blood plasma are subjected to density-gradient
centrifugation, a separation method that depends on the size and mass density (top-down gra-
dient) or mass density only (bottom-up gradient) of particles. Different body ﬂuids require different
approaches with regard to the sample loading approach and choice of density range. The crude
extract can be mixed with the densest fraction and loaded at the bottom of the tube (bottom-up
approach) or the crude extract can be loaded on top of the density gradient (top-down approach). A
bottom-up density gradient is often preferred for the separation of extracellular vesicles because only
vesicular structures are able to ﬂoat upward into the gradient. However, this approach is inferior for
the separation of BEVs from blood plasma, because abundantly present LDLs, VLDLs and chylo-
microns, with a lower density than that of BEVs, also ﬂoat through the BEV density fraction of
interest when using a bottom-up approach. In our experience, this inevitably leads to a reduced
speciﬁcity for BEVs. To ensure separation of BEVs from other biological components in stool, a 50%
(wt/vol) iodixanol layer is added to the bottom-up gradient. HEPA-enclosed automated liquid
handlers enable reproducible, robust and contaminant-free density-gradient separation, and their use
is encouraged in preference to manual density-gradient preparation and fraction collection.
Density-gradient centrifugation of crude extracts obtained from stool and blood plasma returns a
BEV sample with a low efﬁciency (i.e., a substantial loss of BEVs) but high speciﬁcity for BEVs. BEVs
can be analyzed after removal of the density media by an additional SEC step, which is recommended
to further increase speciﬁcity (i.e., a substantial removal of ﬁbers and ﬂagella; Fig. 4c) and to avoid
interference of the density medium with functional assays, electron microscopy and mass
spectrometry–based proteomics35 (Step 28).
General methods for the characterization of BEVs
Post-separation BEVs are characterized in compliance with EV-TRACK and MISEV2018 guide-
lines21,25 (Step 29; Fig. 3). Each preparation of BEVs should be (i) deﬁned by quantitative and
qualitative measures of the source (e.g., mass and type of stool, volume of blood plasma and type
of blood collection tube; see Step 2); (ii) characterized to determine abundance and quality of BEVs
(e.g., by NTA to determine total particle number and by electron microscopy to visualize BEV
ultrastructure, BEV integrity and potential co-separation of components; see Step 29A and 29B);
(iii) tested for presence of content associated with BEVs (e.g., proteomics, western blot and LPS- and
LTA-based assays; see Step 29C–G); and (iv) tested for the absence of other components (e.g.,
proteomics, western blot and ELISA assays for lipoproteins, including apoA-I (HDLs) and apo B
variants (LDLs, VLDLs, chylomicrons); see Step 29C and 29G. Because the ﬁnal BEV concentration
can be a limiting factor in performing all these general characterization methods (in addition to other
functional assays), we advise—in agreement with the EV-TRACK and MISEV2018 guidelines21,25—
full assessment and characterization of BEV preparations for each new experimental design devel-
oped in the lab. On a routine basis, a limited set of characterization methods can be used to deﬁne
BEV preparations (e.g., NTA and western blot).
Transmission electron microscopy (TEM), combined with mass spectrometry–based proteomics,
is able to conﬁrm the speciﬁcity of the protocol for BEVs. Western blot and ELISA analysis can be
used to further conﬁrm the presence of a limited number of membrane-associated BEV proteins and
the lack of some contaminating particles such as EEVs and lipoproteins. BEV markers implemented
in this protocol are not universally expressed across all bacterial species. The choice of BEV and
contaminant markers will rely on the research aim, bacterial species of interest and type of body ﬂuid.
Quantiﬁcation methods such as NTA are the most informative for extracellular vesicles recovered by
separation techniques with the highest speciﬁcity because these methods are not speciﬁc to BEVs and
also register other co-separated biological materials including lipoproteins and protein aggregates.
Therefore, in compliance with the MISEV2018 guidelines, we recommend including complementary
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methods to assess whether quantiﬁcation provides an adequate estimation of BEV number and size.
Absolute extracellular vesicle sizing and counting methods are currently imperfect and will require
further improvement, aided by appropriate reference standards such as those developed by our
group24. Nevertheless, current methods can provide a reasonable indication of the number of particles
per volume, and particle size distributions that are best interpreted when combined with general
(e.g., western blot analysis for positive and negative protein markers) and single-particle analyses (e.g.,
electron microscopy (close-up and wide ﬁeld)). Other methods to characterize BEVs are available and
applicable beside those implemented in this protocol including but not limited to ﬂow cytometry,
tunable resistive pulse sensing, cryo-electron microscopy, atomic force microscopy, dynamic light
scattering and single-particle interferometric reﬂectance imaging. An accurate quantitation of BEVs is
possible only within a certain concentration and size range that varies by platform.
Orthogonal biochemical characterization of BEVs
We have adopted highly sensitive assays that are routinely used to detect pyrogens in pharmaceuticals
and medical devices (Fig. 3; ref. 36). Pathogen-associated molecular patterns (PAMPs) are recognized
by a number of cellular sensors of the innate immunity, which include TLRs. Reporter assays based
on the use of stably TLR-transfected HEK293 cells have been designed to provide a sensitive and
reliable method for the detection of TLR agonists. HEK-Blue/hTLR2 and HEK-Blue/hTLR4 cells co-
express a speciﬁc TLR gene and a TLR-inducible reporter gene encoding the secreted embryonic
alkaline phosphatase (SEAP), allowing TLR stimulation to be monitored. While TLR4 mediates the
inﬂammatory response to LPS (Gram-negative BEVs), TLR2 is more speciﬁcally involved in the
detection of LTA (Gram-positive BEVs). The LAL assay is an alternative characterization technique
that uses the blood of the horseshoe crab Limulus polyphemus to quantify LPS.
Note that positive assay results can be generated by other bacterial or host components. As a
consequence, endotoxin reporter assays are most informative for BEVs recovered with high speci-
ﬁcity. Analysis of electron microscopy images at high resolution and mass spectrometry–based
proteomics of separated BEVs from stool and blood plasma further support the speciﬁcity of
recovered BEVs and the identiﬁcation of BEV subtypes.
Control samples
We recommend the use of control samples to assess endotoxin contamination and to evaluate the
performance of orthogonal biophysical separation and biochemical characterization:
1 Blank sample (negative control). Biochemical characterization of blank sample (e.g., endotoxin-free
PBS) versus blank sample processed by orthogonal biophysical separation allows endotoxin
contamination to be identiﬁed at the level of separation and characterization. The source of
contamination can be diverse, ranging from endotoxin-positive reagents to non-sterile equipment.
2 Blank sample spiked with BEVs (positive control). To practice and validate the orthogonal
biophysical separation and/or biochemical characterization (Box 3), we recommend spiking a blank
sample (e.g., endotoxin-free PBS or healthy donor plasma) with BEVs (e.g., Escherichia coli Nissle
1917 (EcN) BEVs; Box 4). The amount of BEVs spiked depends on the sensitivity of the
implemented characterization method. For the analysis of BEV preparations using the LAL assay, a
spike of 1010 EcN BEVs is sufﬁcient. Western blot requires a spike of 1011 EcN BEVs in order to
maximize the success rate of protein detection. (Speciﬁed BEV numbers were quantiﬁed by NTA.)
Materials
Biological materials
● Blood ! CAUTION Experiments using human samples must conform to local and national regulations.
In this study, collection of blood samples was done according to Ethical Committee of Ghent
University Hospital approvals EC/2014/0655 and EC/2017/0882 and in accordance with the relevant
guidelines. Informed consent must be obtained when using patient plasma. Human body ﬂuids should
be handled in a Biosafety Level 2 (or higher) environment and with strict attention to Biosafety Level 2
procedures. Refer to the Centers for Disease Control and Prevention website (https://www.cdc.gov/
labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF)
● Stool ! CAUTION Experiments using human samples must conform to local and national regulations.
In this study, collection of stool samples was done according to Ethical Committee of Ghent University
Hospital approval EC/2006/377 and in accordance with the relevant guidelines. Informed consent
must be obtained when using patient stool samples. Human body ﬂuids should be handled in a
PROTOCOL NATURE PROTOCOLS
12 NATURE PROTOCOLS |www.nature.com/nprot
Biosafety Level 2 (or higher) environment and with strict attention to Biosafety Level 2 procedures.
Refer to the Centers for Disease Control and Prevention website (https://www.cdc.gov/labs/pdf/
CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF)
Reagents
Sample preparation
● Endotoxin-free PBS (without Ca2+ and Mg2+; Merck Millipore, cat. no. TMS-012-A)
Crude extract preparation
● Trisodium citrate dihydrate (Santa Cruz Biotechnology, cat. no. sc-394274)
● Sepharose CL-2B (GE Healthcare, cat. no. 17014001)
BEV separation
● OptiPrep (60% (wt/vol) iodixanol; Axis-Shield, cat. no. AXS-1114542) c CRITICAL Protect product
from light. Prolonged exposure to direct sunlight leads to release of iodine from the iodixanol
molecule. Shake gently before use.
● Tween 20 (Sigma-Aldrich, cat. no. P1379)
● Sucrose (Sigma-Aldrich, cat. no. S0389)
● EDTA (Titriplex; Merck Millipore, cat. no. 1084180100)
● Tris (VWR, cat. no. 103154M)
● HCl (6.0 N; Alfa Aesar, cat. no. 44921.K2) ! CAUTION HCl is corrosive. Use protective equipment.
Box 3 | Practicing critical steps of the protocol
Some critical steps of the Procedure require hands-on practice in order to obtain consistent results. Examples are
depicted below. Each step shows detailed handling information.
Step 20B. The manual preparation of density gradients can be easily practiced by adding 50 µl of 0.4% (wt/vol)
trypan blue solution to the 40% and 10% (wt/vol) iodixanol solutions. A clear distinction between the different
layers in this colored test density gradient should be visible. (Fig. 5c)
Step 27B. The manual collection of the density-gradient fractions can be practiced by using a colored test gradient
(see above). Ensure that no liquid from the next fraction is pipetted up (visual check by color).
Notice that the performance of the robot-assisted density gradient handling can also be evaluated using this
method.
Step 28A. Spike at least 1 × 1010 EcN BEVs into 2 ml of plasma or PBS and perform SEC (see Box 4 for the
preparation of EcN BEVs). The competence of the researcher in the performance of the technique can be
evaluated by LPS activity measurement of the SEC fractions from the spiked sample. A ﬁrst peak should be visible
in SEC fractions 4–6, and western blot (using anti-LPS or anti-OmpA antibodies) can further validate these
results (Supplementary Fig. 2).
Step 28B. Because the pellet after ultracentrifugation can be easily disturbed, extensive training in the careful
removal of the supernatant is recommended. Start the supernatant removal with 1,000-µl pipette tips, and switch
to 100-µl tips when the remaining volume in the centrifugation tube is approximately 1 ml. Fluorescence labeling
of BEVs can be an added value in practicing this step because a pellet with high concentrations of ﬂuorescently
labeled BEVs is visible to the naked eye45.
Box 4 | Protocol modiﬁcation for BEV separation from an EcN bacterial cell culture ● Timing 48 h
Procedure
Sample collection
1 Add a minimal amount (≈20 mg) of EcN (Mutaﬂor powder) to 250 ml of pre-warmed (37 °C) LB medium
(‘Reagent setup’).
2 Grow bacterial culture overnight at 37 °C with constant rotation (150 r.p.m.). Monitor growth by measuring
the optical density at 600 nm.
3 Perform the Procedure starting from Step 4. Note that, although in this case the majority of BEVs are located
in density fractions 8 and 9, we recommend pooling density fractions 5–9 in Step 27 to maximize the ﬁnal BEV
yield. If option A is followed in Step 28, dilute the pooled fractions to 6 ml with endotoxin-free PBS and use
three SEC columns. If option B is followed in Step 28, transfer half of the pooled density fraction to one
centrifugation tube and the other half to another centrifugation tube (see Step 28B(i)) and pool the pellets
obtained in Step 28B(viii).
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● Endotoxin-free water (Alfa Aesar, cat. no. 15466979)
● Ethanol (Merck Millipore, cat. no. 1070174000)
BEV recovery
● Sepharose CL-2B (GE Healthcare, cat. no. 17014001)
BEV characterization
● Formvar carbon-coated, glow-discharged grids (300 mesh; Agar Scientiﬁc, cat. no. AGS162-3H)
● Bovine serum albumin (Santa Cruz Biotechnology, cat. no. A2153)
● Glutaraldehyde (Sigma-Aldrich, cat. no. G5882)
● Uranyl acetate (Polysciences, cat. no. 21447-25) ! CAUTION Uranyl acetate is both radioactive
and toxic. It is very toxic if ingested or inhaled as dust or upon skin contact if skin is cut or abraded.
Weigh powder in a chemical fume hood.
● Methylcellulose (Sigma-Aldrich, cat. no. M7027)
● Glycerol (Scharlab, cat. no. GL00261000)
● SDS (Sigma-Aldrich, cat. no. 436143-25G) ! CAUTION SDS is toxic upon contact with skin and causes
skin and eye irritation. Always wear protective gloves/clothing and store locked up.
● 2-Mercaptoethanol (Bio-Rad Laboratories, cat. no. 1610710) ! CAUTION Wear personal protective
equipment. Ensure adequate ventilation. Avoid contact with eyes, skin or clothing. Do not breathe
vapors or spray mist. Do not ingest. Keep away from open ﬂames, hot surfaces and sources of ignition.
● Bromophenol blue (Sigma-Aldrich, cat. no. B0126)
● Precast gel, SDS-PAGE 10% (Abcam, cat. no. ab119202)
● E. coli LPS antibody (2D7/1; Abcam, cat. no. ab35654)
● OmpA (outer membrane protein A) antibody (Antibody Research, cat. no. 111120)
● Flotillin-1 antibody (BD Biosciences, cat. no. 610820)
● CD9 antibody (Cell Signaling Technology, cat. no. 13403S)
● ALIX antibody (Cell Signaling Technology, cat. no. 2171S)
● Flagellin antibody (Abcam, cat. no. ab93713)
● ApoA-I antibody (Santa Cruz Biotechnology, cat. no. sc-376818)
● LAL assay (Associates of Cape Cod, cat. no. C1500)
● Control standard endotoxin (10 ng/vial; Associates of Cape Cod, cat. no. EC010-5)
● HEK-Blue-hTLR2 reporter cell line (InvivoGen, cat. no. hkb-htlr2) ! CAUTION HEK293 cells are
biohazardous materials and must be handled according to governmental and institutional regulations
! CAUTION Cell lines should be regularly checked to ensure that they are authentic and not infected
with mycoplasma.
● HEK-Blue-hTLR4 reporter cell line (InvivoGen, cat. no. hkb-htlr4) ! CAUTION HEK293 cells are
biohazardous materials and must be handled according to governmental and institutional regulations
! CAUTION Cell lines should be regularly checked to ensure that they are authentic and not infected
with mycoplasma.
● HEK-Blue detection medium (InvivoGen, cat. no. hb-det2)
● Ficoll-Paque Plus (GE Healthcare Bio-Sciences, cat. no. 17144002)
● RPMI 1640 medium (1×) + GlutaMAX (Thermo Fisher Scientiﬁc, cat. no. 61870-010)
● FCS (Biochrom, cat. no. S0115) c CRITICAL Divide FCS into aliquots and store at −20 °C for up to
1 year. Avoid freeze–thaw cycles.
● Luminex assay (human cytokine/chemokine Luminex array, 65-plex panel; Eve Technologies)
● Silica Microspheres, 0.1 µm, colloidal (Polysciences, cat. no. 24041-10)
● Formic acid (Merck, cat. no. 5438040250)
● Acetonitrile (Thermo Fisher Scientiﬁc, cat. no. 10660131)
Box 3
● Trypan blue solution (0.4% (wt/vol); Thermo Fisher Scientiﬁc, cat. no. 15250061)
Box 4
● EcN (Mutaﬂor; Ardeypharm)
● Tryptone (Hispanlab S.A., cat. no. H1612)
● Yeast extract (Hispanlab SA, cat. no. H1702)
● NaCl (Sigma-Aldrich, cat. no. S1679)
● NaOH (VWR, cat. no. 1091411000)
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Equipment
Sample collection
● Opaque, wide-mouth container (100-ml container with screw cap; Sarstedt, cat. no. 75.562.011)
● Blood collection tubes (3.2% (wt/vol) sodium citrate; MLS, cat. no. KG455322)
● BioDrop DUO spectrophotometer (BioDrop, cat. no. 80-3006-61.01)
Sample preparation
● Laminar ﬂow cabinet (class II or III)
● Hematology analyzer (Sysmex, model no. XP-300)
● High-speed centrifuge (Beckman, model no. J2-21)
● Fixed-angle aluminum rotor + 500-ml centrifugation cups (Beckman Coulter, model no. JA-10,
cat. no. 369687)
● Benchtop centrifuge (Eppendorf, model no. 5810 R)
● Polypropylene tubes (50 ml; Greiner Bio One, cat. no. 210261)
● Tube rotator (RotoFlex; Argos Technologies, cat. no. R2001)
● Serological pipettes (5 and 25 ml; nerbe plus, cat. nos. 12-441-9105 and 12-481-9102)
● Electronic pipettor
● Magnetic stirrer
Crude extract preparation
● Bottle-top ﬁlter (0.22 µm; Millipore Express PLUS, 0.22 µm; Merck Millipore, cat. no. GPWP09050)
● Vacuum pump
● Glass bottle
● Syringe (10 ml; Romed, cat. no. 3SYR-10ML) c CRITICAL A difference in the diameter of the syringes
clearly impacts the SEC performance. Therefore, we recommend using this particular syringe or
a syringe with identical dimensions. Validate Step 28A if using another syringe.
● Nylon-net ﬁlters (20-µm pore size; Merck Millipore, cat. no. NY2002500)
● Tripod
● Translucent vial
● Centrifugal ﬁlter (10 kDa; Amicon Ultra, 2 ml; Merck Millipore, cat. no. UFC201024)
● Centricon Plus-70 centrifugal ﬁlter units (10 kDa; Merck Millipore, cat. no. UFC701008)
● Paraﬁlm (Bemis Company, cat. no. PM-996)
BEV separation
● Ultracentrifuge (Optima XPN-80 Ultracentrifuge; Beckman Coulter, model no. A99839)
● Thin-walled polypropylene tubes (17 ml; Beckman Coulter, cat. no. 337986) Tubes are placed in an
aluminum box and sterilized using hot air sterilization (120 min at 150 °C)
● SW 32.1 Ti Swinging-bucket rotor + SW 32.1 Ti rotor bucket set (Beckman Coulter, cat. no. 369651)
● Biomek 4000 Laboratory Automation Workstation (Beckman Coulter, cat. no. A99749)
BEV characterization
● Microscope (NanoSight, model no. LM10) equipped with 405-nm laser
● Syringe pump (NanoSight)
● Transmission electron microscope (Thermo Fisher Scientiﬁc FEI, Tecnai Spirit model)
● Quemesa charge-coupled device camera (Olympus Soft Imaging Solutions)
● Qubit Fluorometer 3.0 (Thermo Fisher Scientiﬁc, cat. no. Q33216)
● Thermomixer (Eppendorf, cat. no. 5355 000.011)
● Plate (96 wells, Nunclon Delta Surface; Thermo Fisher Scientiﬁc, cat. no. 167008)
● Cell culture incubator (IncuSafe CO2 incubator; PHCbi, cat. no. MCO-230AIC-PE)
● Live-cell analysis system (IncuCyte Zoom; Essen Bioscience, serial no. ZOOM41000)
● Paradigm Detection Platform (Beckman Coulter)
● Centrifugal ﬁlter (3 kDa; Amicon Ultra-15ml; Merck Millipore, cat. no. UFC900308)
● Centrifugal ﬁlter (100 kDa; Amicon Ultra-2ml; Merck Millipore, cat. no. UFC210024)
Box 4
● Shaker (G10 Gyrotory shaker; New Brunswick Scientiﬁc, cat. no. LV38337702)
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Software
● NTA Software v.3.0 (NanoSight,https://www.malvernpanalytical.com/)
● MaxQuant software (https://www.maxquant.org/)
Reagent setup
Gradient buffer A
To prepare 1 liter of buffer, dissolve 0.25 M sucrose, 6 mM EDTA and 60 mM Tris in 800 ml of
endotoxin-free water (use magnetic stirrer). Adjust the pH to 7.4 with HCl (6 M). Dilute the buffer to
1 liter with endotoxin-free water. Filter the buffer with a 0.22-µm bottle-top ﬁlter. The buffer can be
stored at 4 °C for up to 6 months. Prepare the buffer at least 1 d before use, because the complete
dissolution of the compounds can take several hours. c CRITICAL Tris and EDTA are known to
interfere with the organization of LPS in bacterial cell membranes37. Tris and EDTA concentrations
reported in our protocol and others38 do not impact BEV membrane structure, as evidenced by electron
microscopy, presence of intraluminal proteins and consistency of LPS measurement assays. Validation
by comparative evaluation of density-gradient buffers (Tris–EDTA versus HEPES–NaCl) is needed in
the ﬁeld to objectively assess technology performance12.
Gradient buffer B
To prepare 1 liter of buffer, dissolve 0.25 M sucrose, 1 mM EDTA and 10 mM Tris in 800 ml of
endotoxin-free water (use magnetic stirrer). Adjust the pH to 7.4 with HCl (6 M). Dilute the buffer to
1 liter with endotoxin-free water. Filter the buffer using a 0.22-µm bottle-top ﬁlter. The buffer can be
stored at 4 °C for up to 6 months. Prepare at least 1 d before use, because the complete dissolution of
the compounds can take several hours. c CRITICAL Tris and EDTA are known to interfere with the
organization of LPS in bacterial cell membranes37. Tris and EDTA concentrations reported in our
protocol and others38 do not impact BEV membrane structure, as evidenced by electron microscopy,
presence of intraluminal proteins and consistency of LPS measurement assays. Validation by com-
parative evaluation of density-gradient buffers (Tris–EDTA versus HEPES–NaCl) is needed in the ﬁeld
to objectively assess technology performance12.
Sample-reducing buffer
This buffer is 0.5 M Tris-HCl (pH 6.8), 40% (vol/vol) glycerol, 9.2% (wt/vol) SDS, 3% (vol/vol)
2-mercaptoethanol and 0.005% bromophenol blue. The buffer can be stored at −20 °C for up to
6 months. ! CAUTION SDS is toxic upon contact with the skin and causes skin and eye irritation.
Always wear protective gloves and clothing and store locked up. ! CAUTION 2-mercaptoethanol is toxic
if swallowed or inhaled. Wear personal protective equipment. Ensure adequate ventilation. Avoid
contact with eyes, skin or clothing. Do not breathe vapors or spray mist. Do not ingest. Keep away from
open ﬂames, hot surfaces and sources of ignition.
LB medium
Weigh the following reagents: 10 g of tryptone, 5 g of yeast extract and 5 g of NaCl. Dissolve them in
950 ml of dH2O and adjust the pH to 7.3, if necessary, by adding either HCl or NaOH solution. Bring
the volume to 1 liter with dH2O and sterilize by autoclaving for 15 min at 121 °C. LB can be stored
at 4 °C for up to 1 month.
Methylcellulose–uranyl acetate solution
Add 0.4 g of methylcellulose to 20 ml of boiling endotoxin-free water. Stir for 4–8 h on ice. Add
80 mg of uranyl acetate. Let stand for at least 24 h at 4 °C. Store at 4 °C for up to 1 month.
Equipment setup
SEC column
Wash the Sepharose beads three times by performing gravity sedimentation (wait at least 2 h to
obtain complete sedimentation) and decanting the upper liquid. Replace the liquid each time with
endotoxin-free PBS (1 volume of PBS per 2 volumes of beads) and mix thoroughly. Place a quarter of
a Nylon-net ﬁlter with a 20-µm pore size on the bottom of a 10-ml syringe. Add 10 ml of washed
Sepharose beads to the syringe. Make sure the column never becomes dry. Close the lower opening of
the syringe with a stopper and the upper opening with Paraﬁlm. Columns can be stored at 4 °C for up
to 1 week.
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NTA
Calibrate the NanoSight LM10 instrument with known concentrations of 100-nm silica microspheres
to obtain optimum acquisition detector settings and post-acquisition settings. Record three 60-s
videos and analyze them with camera level 13 and detection threshold 3. However, variations between
different NTA instruments may occur, so a critical assessment of the settings is required for each
instrument.
Procedure
c CRITICAL We provide the procedure below for collection and analysis of stool samples as an example.
See Box 2 for details of how to apply the procedure to the analysis of blood samples.
Sample collection ● Timing 5 min
1 Collect stool in an opaque, wide-mouth container (with integrated spoon, optionally). We
recommend measuring stool consistency with the BSS. This protocol is optimized for stool samples
with a BSS category of 3 or 4. Differences in BSS scores impact the stool species’ richness32,
suspension efﬁciency (Step 3) and BEV recovery.
! CAUTION Experiments using human samples must conform to local and national regulations. In
this study, collection of stool samples was done according to Ethical Committee of Ghent
University Hospital approval EC/2006/377 and in accordance with the relevant guidelines.
Informed consent must be obtained when using patient stool samples.
c CRITICAL STEP Freeze–thaw cycles and short-term storage of stool impact BEV concentrations
(Fig. 4a). In addition, a change in BEV integrity and composition due to cargo leakage cannot be
excluded. Researchers are required to develop standard operating procedures for studies intended
to create reliable biorepositories of stool samples. Data in this protocol were obtained with fresh
stool samples.
Sample preparation ● Timing 1 h 10 min
c CRITICAL For considerations in regard to sterility and the risk of endotoxin contamination, all
further steps are performed in a laminar ﬂow cabinet (class II or III). The use of sterile gloves (with low
endotoxin levels) is recommended.
2 Use the spoon to transfer a minimal amount of stool (e.g., 5 g) to a pre-weighed 50-ml tube.
3 Add pre-warmed (37 °C) endotoxin-free PBS (e.g., 50 ml) to the tube and suspend the stool sample
by constant 360° rotation (in a RotoFlex for 30 min at 37 °C; Fig. 5a). During this step, cool the
high-speed centrifuge and JA-10 rotor to 4 °C.
c CRITICAL STEP Sufﬁcient speed and duration of rotation are essential to ensuring complete
suspension of the stool sample. In addition, too high a stool/PBS ratio leads to saturation during
suspension and a relatively lower yield of BEVs (Fig. 4b). A maximum sample concentration of 10%
(wt/vol) is recommended (e.g., dissolve 5 g of stool in ≥50 ml of PBS).
c CRITICAL STEP We recommend also preparing a blank sample (e.g., endotoxin-free PBS) for
orthogonal biophysical separation followed by biochemical characterization as described in Step 29.
This blank sample serves as a control and allows any contamination to be detected.
4 Transfer the suspended stool sample to a sterile centrifugation cup.
5 Place the centrifugation cup into the high-speed centrifuge and centrifuge at 8,000g for 15 min at
4 °C. Symmetrically balance the load and use a counterbalance when needed.
6 Collect the supernatant, using a serological pipette and an electronic pipettor, and transfer it to a
new sterile centrifugation cup.
c CRITICAL STEP Avoid transferring or disturbing any pellet, because these contain contaminating
material such as ﬁbers, bacteria, undigested food.
7 Place the new centrifugation cup into the high-speed centrifuge and centrifuge at 8,000g for 15 min
at 4 °C. Symmetrically balance the load and use a counterbalance when needed.
Crude extract preparation ● Timing 1 h 30 min
8 During Step 7, set up the ﬁltration apparatus, using a sterile bottle-top ﬁlter (0.22 µm). Place a
sterile glass bottle on ice, screw the ﬁlter onto the bottle and ﬁrmly attach it to a vacuum pump (see
Fig. 5b for experimental setup).
9 Collect the supernatant from Step 7, using a serological pipette and electronic pipettor, and transfer
it to the bottle-top ﬁlter from Step 8.
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c CRITICAL STEP Avoid transferring or disturbing any pellet, because these contain contaminating
material such as ﬁbers, bacteria, undigested food.
10 Turn on the vacuum pump and wait until all the sample has passed through the ﬁlter and has been
collected in the glass bottle.
? TROUBLESHOOTING
11 Use a serological pipette and electronic pipettor to place the ﬁltrate into the concentrate cup of a
10-kDa Millipore Centricon Plus-70 centrifugal ﬁlter unit.
12 Centrifuge the ﬁlter unit at 3,000g for at least 30 min at 4° C until the sample is concentrated to at
least 667 µl (≈1 cm of remaining sample; this can be checked visually). See Step 19 for the rationale
behind this volume. Symmetrically balance the load and use a counterbalance when needed.
c CRITICAL STEP Frequent visible checking of the concentrate at several time points (e.g., 30, 40
and 45 min) is critical in order to avoid too extensive concentration of the sample, because this will
decrease BEV quality and quantity.
13 According to the usage guidelines provided by Millipore, turn the concentrate cup upside down and
place it on top of the sample ﬁlter cup.
14 Place in the benchtop centrifuge and spin at 1,000g for 2 min at 4 °C. Symmetrically balance the
load and use a counterbalance when needed.
15 Collect the sample and dilute it (if needed) to 667 µl with pre-cooled endotoxin-free PBS. Place
immediately on ice.
j PAUSE POINT Crude extracts can be used immediately or stored at −80 °C for several months.
BEV separation ● Timing 20 h
16 Before the preparation of the density gradient (Steps 17–20), bring the SW 32.1 Ti rotor (placed on
a holder) and buckets (placed in a rack) to 4 °C. Turn on the ultracentrifuge and cool it to 4 °C.
17 Prepare a working solution by mixing 1 volume of gradient buffer A (‘Reagent setup’ section) with
5 volumes of OptiPrep. For each density gradient, a minimal total volume of 8.4 ml is required
a b
d e
Pre-cooled tube rack
Iodixanol solutions reservoir
Tip boxes
Pipettor
Sample rack
ManualRobot-assisted
Density gradient preparation
cStep 3 Step 10 Step 20
Step 28Steps 20 and 27
Step-by-step visualization of the BEV separation protocol. a, In Step 3, the stool sample is suspended in PBS by
constant 360° rotation using the RotoFlex. b, To obtain a ﬁnal crude extract from the stool sample, the sample is
passed through a bottle-top ﬁlter with a pore size of 0.22 µm (Step 10). Ensure that the ﬁlter is ﬁrmly screwed onto
the bottle and attached to a vacuum pump. Place the bottle on ice. c, In Step 20, a density gradient is prepared as a
ﬁrst step to separate BEVs from the crude extract. We recommend robot-assisted preparation of density gradients
(option A) but also provide a manual method (option B). To practice this step, add trypan blue solution to the 40%
and 10% (wt/vol) iodixanol solutions (see Box 3). A clear delineation should be visible between the different layers.
d, An illustrative overview of the Biomek 400 automated workstation, which can be used for the preparation and
fraction collection of density gradients. e, In Step 28, SEC can be used for the recovery of BEVs. The SEC column is
placed in a tripod, and fractions can be collected in Eppendorf tubes.
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(≈1.4 ml of gradient buffer A + 7 ml of OptiPrep). Prepare fresh working solution for each
experiment.
18 Prepare the 10%, 20% and 40% (wt/vol) iodixanol solutions according to the following table (a 20%
excess in stock volume has already been taken into account). Prepare fresh solutions for each
experiment and store them on ice in anticipation of further use. See ‘Reagent setup’ section for the
detailed description of the preparation of gradient buffer B.
Iodixanol solution (wt/vol%) Working solution from Step 17 (ml) Gradient buffer B (ml)
10 1 4
20 2 3
40 4 1
19 Prepare a 50% (wt/vol) iodixanol sample solution by mixing 667 µl of the sample from Step 15 with
3.33 ml of OptiPrep. (OptiPrep is a 60% (wt/vol) solution of iodixanol in water, so the ﬁnal
iodixanol concentration of this mixture is 50%). Ensure that the solution is homogeneous by
pipetting up and down.
? TROUBLESHOOTING
20 For the preparation of density gradients, we recommend the robot-assisted preparation technique
(option A). This state-of-the-art approach increases protocol repeatability and contributes to
operator-independent BEV separation. However, we also provide a step-by-step procedure for
manual preparation of density gradients in case an automated liquid handler is not available
(option B).
(A) Robot-assisted preparation of density gradients ● Timing 20 min per set of three density
gradients
c CRITICAL To ensure sterility during the preparation of density gradients, we recommend
using an automatic liquid handler equipped with a positive-pressure HEPA enclosure.
(i) Start the robot (e.g., a Biomek 400 automated workstation) and software.
(ii) Open the density-gradient script. The script was designed in close collaboration with
Beckman Coulter.
(iii) Place the tip boxes, pre-cooled iodixanol solutions reservoir, pipettor, sample rack and
pre-cooled tube rack with the centrifugal tube in one of the 12 deck positions of the
workstation (Fig. 5d).
(iv) Fill the reservoir with the freshly made iodixanol solutions from Steps 18 and 19.
(v) Start the density-gradient script. (Supplementary Video 1 shows a part of the robot-assisted
preparation of a density gradient.)
(B) Manual preparation of density gradients ● Timing 20 min per density gradient,
depending on the experience of the researcher
c CRITICAL The preparation of high-quality density gradients is essential in order to obtain
high recovery efﬁciencies and adequate separation of BEVs from contaminants. Therefore,
hands-on training is recommended (Box 3).
(i) Carefully transfer 4 ml of the sample containing 50% (wt/vol) iodixanol solution from
Step 19 to the bottom of a thin-walled polypropylene centrifugation tube.
(ii) Slowly tilt the tube to 70° and carefully transfer (drop by drop) 4 ml of the 40% (wt/vol)
iodixanol solution to the surface of the liquid (close to the opening of the tube; Fig. 5c).
Preferentially, use a P1000 pipette (transfer 4 × 1,000 µl).
(iii) Carefully transfer (drop by drop) 4 ml of the 20% (wt /vol) iodixanol solution to the surface
of the liquid (close to the opening of the tube). Preferentially, use a P1000 pipette (transfer
4 × 1,000 µl).
(iv) Carefully transfer (drop by drop) 3.5 ml of the 10% (wt/vol) iodixanol solution to the
surface of the liquid (close to the opening of the tube). Preferentially, use a P1000 pipette
(transfer 4 × 875 µl).
(v) Carefully transfer (drop by drop) 1 ml of endotoxin-free PBS to the surface of the liquid
(close to the opening of the tube). Preferentially, use a P1000 pipette.
c CRITICAL STEP We recommend not to place the tube upright between these different
steps because this negatively affects the density-gradient quality. In the case of preparation
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of several density gradients, place the ﬁnished gradients upright on ice or, preferentially,
use other pre-cooled (−20 °C) devices especially made for tubes (Fig. 5d).
? TROUBLESHOOTING
21 Open the lid of the ultracentrifuge and place the pre-cooled SW 32.1 Ti rotor into the
ultracentrifuge. Close the lid.
22 Carefully place the centrifugation tube from Step 20 into the pre-cooled bucket.
23 Open the lid and carefully place the buckets into the rotor. Symmetrically balance the load and use
a counterbalance when needed. A tube ﬁlled with Tween 20 can be used as a counterbalance
because its density is similar to that of the iodixanol density gradient. Close the lid.
24 Enter the following parameters into the software of the ultracentrifuge:
Parameter Value
Speed 100,000g
Time 18 h
Temperature 4 °C
Acceleration proﬁle 0 (0: maximum; 10: minimum)
Deceleration proﬁle 9 (0: maximum; 10: minimum)
c CRITICAL STEP A change in one of these parameters will inevitably lead to a density shift in the
ﬁnal fractions. The acceleration occurs as quickly as possible, and the deceleration proﬁle is the
second-slowest program provided by the Beckman Coulter software of the Optima XPN-80
ultracentrifuge. Do not use a deceleration proﬁle of 10 because of the extreme length of time it
would take for the rotor to come to a stop (no braking is applied).
25 Start the ultracentrifuge.
26 After completion of the ultracentrifugation, open the lid and carefully place the buckets in a rack. In
the case of several density gradients, place only one bucket in the rack and leave the others in the
cold ultracentrifuge if you proceed with option B in step 27. If option B is to be followed in Step 28,
do not turn off the ultracentrifuge; instead, bring the buckets to 4 °C after the ultracentrifugation
and again cool the centrifuge to 4 °C.
27 Take the centrifugation tube out of the bucket and perform a robot-assisted (option A) or manual
(option B) density-gradient fraction collection. As in Step 20, we recommend using option A to
achieve higher protocol repeatability and increase standardization.
(A) Robot-assisted density-gradient fraction collection ● Timing 8 min per density gradient
c CRITICAL To ensure sterility during the density-gradient fraction collection, we recommend
using an automatic liquid handler equipped with a positive pressure HEPA enclosure.
(i) Start the robot (e.g., a Biomek 400 automated workstation) and software.
(ii) Open the fraction collection script. The script was designed in close collaboration with
Beckman Coulter.
(iii) Place the tip boxes, pipettor, sample rack and pre-cooled tube rack with centrifugal tube
into one of the 12 deck positions of the workstation (Fig. 5d).
(iv) Start the fraction collection script.
(v) Pool density fractions 8 and 9 (these contain the BEVs) and immediately place them on ice.
(Fractions are numbered starting from the top.)
(B) Manual density-gradient fraction collection ● Timing 15 min per density gradient,
depending on the experience of the researcher
(i) Carefully collect 1-ml fractions from the top of the centrifugation tube by slowly pipetting
1 ml from the center of the liquid surface of the density gradient. Use a P1000 pipette with
precise control to transfer the density fractions to sterile sample tubes and immediately
place them on ice. The ﬁnal density of the collected fractions can be determined by making
a standard curve of the absorbance values at 340 nm of 1:1 aqueous dilutions of 5, 10, 20
and 40% iodixanol.
c CRITICAL STEP Hold the centrifugation tube between your thumb and foreﬁnger and
make sure the tube stays upright.
? TROUBLESHOOTING
(ii) Pool density fractions 8 and 9 (as these contain the BEVs) and immediately place them on
ice. Depending on the research goal, other density fractions can also be collected and
PROTOCOL NATURE PROTOCOLS
20 NATURE PROTOCOLS |www.nature.com/nprot
processed in the same way. For example, EEVs are present in lower-density fractions 5–7,
as previously shown6.
BEV recovery
28 Depending on the planned downstream characterization, we propose two different procedures for
retrieving BEVs from density fractions. OptiPrep remnants in separated BEVs can interfere with
downstream approaches such as functional activity assays39. Complete removal of iodixanol is
desirable. Iodixanol removal can be achieved by SEC (option A)35. In the case that only robust
detection analyses are intended (e.g., western blotting), option B (ultracentrifugation) can be
performed to minimize the hands-on time. We do recommend option A because the highest BEV
speciﬁcity is obtained with this procedure, as evidenced in Fig. 4c.
(A) SEC ● Timing 30 min
(i) Place the SEC column into a tripod (see Fig. 5e for experimental setup). The detailed
description of the preparation of the column can be found in the ‘Equipment setup’
section.
(ii) Pre-rinse the column with endotoxin-free PBS (use at least 10 ml of PBS).
c CRITICAL STEP When loading PBS (or the sample) onto the column, make sure you do
not disturb the Sepharose beads in the column. Load drop by drop and close to the surface
of the column (Supplementary Video 2).
c CRITICAL STEP Before sample loading, collect the eluate in a translucent vial, because
this is the time point at which to check whether the column is leaking Sepharose beads. The
presence of beads in the eluate can be easily checked by phase-contrast microscopy
imaging, because these beads have a size of 60–200 µm.
? TROUBLESHOOTING
(iii) Load pooled density fractions 8 and 9 (= 2 ml) from Step 27 onto the column.
(iv) Immediately after loading the sample onto the column, start collecting 1- ml SEC fractions.
The ﬁrst 3 ml is void volume, SEC fractions 4–7 contain the BEVs. Iodixanol elution starts
with SEC fraction 835.
c CRITICAL STEP Ensure that the SEC column never becomes dry. Reload with endotoxin-
free PBS when the entire sample has penetrated the column.
(v) Concentrate SEC fractions 4–7 with a 10-kDa centrifugal ﬁlter to reduce the volume to
100 µl and increase the BEV concentration.
c CRITICAL STEP The choice of centrifugal ﬁlter is critical and impacts the ﬁnal recovery
of the protocol. Regenerated cellulose membranes with a pore size of 10 kDa recover
extracellular vesicles the most efﬁciently35.
(B) Ultracentrifugation ● Timing 3 h 30 min
(i) Transfer pooled density-gradient fractions 8 and 9 (= 2 ml) from Step 27 to a new
thin-walled polypropylene centrifugation tube.
(ii) Add 13 ml of pre-cooled endotoxin-free PBS to the sample and mix the solution in the tube
by pipetting up and down.
(iii) Carefully place the centrifugation tube into the pre-cooled bucket.
(iv) Open the lid of the ultracentrifuge and carefully place the buckets into the rotor.
Symmetrically balance the load and use a counterbalance when needed. Close the lid.
(v) Enter the following parameters into the ultracentrifuge software:
Parameter Value
Speed 100,000g
Time 3 h
Temperature 4 °C
Acceleration proﬁle 0 (0: maximum; 10: minimum)
Deceleration proﬁle 0 (0: maximum; 10: minimum)
(vi) Start the ultracentrifuge.
(vii) After completion of the ultracentrifugation, open the lid and carefully place the buckets
into a rack. In the case of several ultracentrifugation tubes, place only one bucket in the
rack and leave the others in the cold centrifuge.
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(viii) Take the centrifugation tube out of the bucket and carefully remove and discard all the
supernatant until only 30 µl remains in the middle of the bottom of the tube.
c CRITICAL STEP The pellet is easily disturbed or pipetted; therefore, careful removal of
the supernatant is recommended. Training to carry out this step is essential (Box 3).
(ix) Collect the pellet and dilute it to 100 µl with pre-cooled (4 °C) endotoxin-free PBS. In our
experience, a substantial proportion of BEVs stick to the bottom of the tube after pellet
collection. Therefore, we recommend pipetting the pellet up and down before collection
and rinse the bottom of the tube with the PBS used for dilution.
j PAUSE POINT BEVs can be used immediately or stored at −80 °C for up to several
months.
BEV characterization
29 We have included different procedures for BEV characterization; use option A for NTA, option B
for TEM, option C for western blotting, option D for LPS activity measurements, option E for
TLR2/TLR4 activity measurements, option F for PBMC stimulation experiments, or option G for
proteomic analysis. We use a BEV suspension with a ﬁnal volume of 100 µl.
As described in Step 3, we recommend concurrently performing orthogonal biophysical
separation of a blank sample, followed by biochemical characterization of the ﬁnal sample. This
blank sample serves as a protocol control and will allow detection of any contamination.
(A) NTA ● Timing 10 min per sample
(i) Make a 1:10 serial dilution of the BEV suspension in PBS to reach a concentration within
the detection range of the device (e.g., for the NanoSight LM10 instrument: 3 × 108–1 × 109
particles/ml). In our experience, a minimal 1:5,000 dilution is required if starting from
1.25 g of stool sample.
(ii) Perform NTA on the diluted samples according to the instructions provided by the
manufacturer. Using a NanoSight LM10 device, record at least three 60-s videos and
analyze them with camera level 13 and detection threshold 3. Preferably, a syringe pump
system (recommended infusion rate: 20 arbitrary units) is integrated into the setup in order
to increase the statistical power of the measurement.
? TROUBLESHOOTING
(B) TEM ● Timing 1 h per sample
(i) Use a pipette to place 5–10 µl of the BEV sample on Formvar carbon-coated, glow-
discharged grids. Incubate for 20 min.
(ii) Wash the grids two times for 1 min each in 100 µl of endotoxin-free PBS.
(iii) Fix the sample by incubating the grid in 100 µl of 1% (wt/vol) glutaraldehyde in endotoxin-
free PBS for 5 min.
(iv) Wash the grids eight times for 1 min each in 100 µl of endotoxin-free water.
(v) Stain the grids with neutral 2% (wt/vol) uranyl acetate in endotoxin-free water (50 µl)
for 5 min.
(vi) Immerse the grids in the methylcellulose–uranyl acetate solution (50 µl, see ‘Reagent
setup’) for 10 min on ice. Dry at room temperature.
(vii) Examine the sample in a Tecnai Spirit transmission electron microscope.
(viii) Capture low- and high-magniﬁcation images with a Quemesa charge-coupled device camera.
c CRITICAL STEP Optionally, immuno-EM can also be performed by using, for example,
antibodies against E. coli LPS.
? TROUBLESHOOTING
(C) Western blotting ● Timing 20 h
(i) Measure the protein concentration of the BEV samples with a protein assay according to
the guidelines provided by the manufacturer. We recommend the Qubit ﬂuorometric assay,
because we previously showed that this technique measures (low) extracellular vesicle
concentrations the most accurately with the lowest variation among technical and
biological replicates35.
(ii) Dilute the sample to 1 µg/µl (if possible) with sample-reducing buffer (see ‘Reagent setup’
section).
(iii) Boil the sample for 5 min at 95 °C (900 r.p.m.) in a thermomixer.
(iv) Load a maximum of 30 µg (= 30 µl) of your sample into a well of a SDS–polyacrylamide
gel.
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(v) Perform western blotting as detailed in ref. 40. We recommend staining the samples for
BEV markers (e.g., OmpA), contaminating EEV markers (e.g., Flotillin-1, CD9 and ALIX)
and contaminating protein markers (e.g., Flagellin).
? TROUBLESHOOTING
(D) LPS activity measurements ● Timing 2 h
(i) Make a 1:10 serial dilution of the BEV suspension. In our experience, the lower detection
limit of Gram-negative BEVs for LPS activity measurement is 1.56 × 105 BEVs/ml.
(ii) Perform the LAL assay according to the manufacturer’s guidelines.
c CRITICAL STEP Prepare a fresh set of dilutions from the stock endotoxin solution before
each test to set up a standard curve. All controls, samples and endotoxin standard series
should be tested at least in duplicate. Temperature and reaction timings of the assay are
critical.
(iii) Analyze the samples using the Paradigm Detection Platform with SoftMax Pro 6.1 software.
? TROUBLESHOOTING
(E) TLR2/TLR4 activity measurements ● Timing 18 h
(i) Make a 1:10 serial dilution of the BEV suspension. In our experience, the lower detection
limit of BEVs for TLR4 activity measurement is 4.67 × 106 Gram-negative BEVs/ml and for
TLR2 activity measurement is 108 stool-derived BEVs/ml.
(ii) Perform the TLR2/TLR4 activity measurements using HEK293 reporter cell lines according
to the instructions provided by the manufacturer.
c CRITICAL STEP As clearly stated in the datasheet for these reporter cell lines, use
low-passage cells and passage the cells when 70–80% conﬂuency is reached in order
to guarantee the quality and sensitivity of the cells. Conﬂuency can be determined
in a standardized and objective way using the conﬂuency mask tool of the IncuCyte
technology.
(iii) Analyze the samples with the Paradigm Detection Platform using SoftMax Pro 6.1 software.
? TROUBLESHOOTING
(F) PBMC stimulation experiments ● Timing 1 d 4 h
(i) Isolate PBMCs, starting from 4 ml of blood, using Ficoll-Paque PLUS density-gradient
medium according to the manufacturer’s guidelines.
! CAUTION Experiments using human samples must conform to local and national
regulations. In this study, collection of blood samples was done according to Ethical
Committee of Ghent University Hospital approvals EC/2014/0655 and EC/2017/0882 and
in accordance with the relevant guidelines. Informed consent must be obtained when using
patient blood samples.
(ii) Dilute the PBMCs to 1.33 × 107 PBMCs/ml with pre-warmed (37 °C) RPMI cell culture
medium supplemented with 5% FCS.
(iii) Add 150 µl of the PBMC solution to a well of a 96-well plate and let the PBMCs adhere for
2 h (37 °C, 5% CO2).
(iv) Carefully remove the cell medium and replace it with pre-warmed (37 °C) serum-free
RPMI. Repeat this step two times.
c CRITICAL STEP Slow removal of the medium is essential in order to avoid extensive loss
of PBMCs.
(v) Add BEVs to the PBMCs. In our experience, concentrations down to 107 BEVs/ml can
be used.
(vi) Incubate for at least 24 h. Note that some of the cytokines are released immediately after
PBMC stimulation (e.g., tumor necrosis factor (TNF)-α; Supplementary Fig. 1). In addition
to the short stimulation experiment, we encourage researchers to record videos to visualize
the PBMC stimulation and differentiation. Therefore, use a live cell analysis system and
record a video by taking a picture every 2 h (Supplementary Videos 3 and 4).
(vii) Collect the medium.
(viii) Remove cell debris by centrifugation at 500g for 9 min at 4 °C. Symmetrically balance the
load and use a counterbalance when needed. Collect the supernatant.
(ix) Remove the BEVs from the supernatant by ultraﬁltration with a 100-kDa centrifugal ﬁlter
(3,000g, 10 min, 4 °C). Symmetrically balance the load and use a counterbalance when
needed. Continue with the ﬂow-through.
(x) Concentrate the BEV-free ﬂow-through with a 3-kDa centrifugal ﬁlter (3,000g, 10 min,
4 °C). Symmetrically balance the load and use a counterbalance when needed.
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(xi) Perform a Luminex assay on the concentrate, using a human cytokine/chemokine panel
according to the instructions provided by the manufacturer.
? TROUBLESHOOTING
(G) Proteomic analysis ● Timing 24 h
(i) Process BEV samples for LC-MS/MS analysis using the widely described ﬁlter-aided
sample preparation (FASP) protocol41.
(ii) Load desalted peptides on a nanoﬂow HPLC system coupled to a Q Exactive HF Hybrid
Quadrupole-Orbitrap mass spectrometer equipped with a nano-electrospray ionization
source.
(iii) Use the following speciﬁcations when performing LC-MS/MS analysis: the mobile phase
consists of 0.1% formic acid (solvent A) and acetonitrile/water (95:5 (vol/vol)) with 0.1%
formic acid (solvent B). Separate the peptides with a 50-min gradient from 8 to 35% of
solvent B. Before the end of the run, raise the percentage of solvent B to 100% within 5 min
and keep it there for 5 min. Perform a full MS scan over the mass-to-charge (m/z) range of
300–1,750 with a resolution of 120,000, followed by data-dependent acquisition with an
isolation window of 2.0 m/z and a dynamic exclusion time of 30 s. Fragment the top 12
ions by higher-energy collisional dissociation with a normalized collision energy of 27%
and scan over the m/z range of 200–2,000 with a resolution of 15,000. After the MS2 scan
for each of the top 12 ions is obtained, acquire a new full mass spectrum scan and repeat
the process until the end of the 60-min run. Perform three repeated runs per sample.
(iv) Use the MaxQuant software to search the tandem mass spectra against a database
containing both reviewed and unreviewed sequences of Homo sapiens and common gut
microbes (Prevotella, Bacteroides, Clostridiales and Mitsuokella, based on the ‘frequent
microbe proteins’ dataset provided by Qin et al.42), including different isoforms. We also
recommend the use of automatic metagenome annotation servers such as GhostKOALA43.
? TROUBLESHOOTING
Troubleshooting
Troubleshooting advice can be found in Table 1.
Table 1 | Troubleshooting table
Step Problem Possible reason Solution
10 Sample passes very slowly through
the ﬁlter or stops ﬂowing
Vacuum is lost because of inappropriate
ﬁltration setup
The ﬁlter membrane is blocked by
contaminants
Check whether the ﬁlter fully encloses the
opening of the bottle
Collect the remaining supernatant from the top
chamber of the bottle-top ﬁlter and replace
the ﬁlter
19 Air bubbles are present in the sample Due to the high viscosity of the sample,
air bubbles form easily and can disturb
the density gradient
Remove air bubbles from your sample by gently
squeezing a wash bottle containing 70–100%
ethanol, with the inner straw removed, to blow
vapor over the surface of each well. The air
bubbles will immediately burst
20B No clear delineation is visible between
iodixanol layers of the density gradient
Iodixanol layers are mixed Prepare a new density gradient. We recommend
ﬁrst practicing this step (see Box 3). Ensure that
the gradients are freshly made
27B(i) Absorbance values >1.2 during density
measurements
Iodixanol concentrations >35% (wt/vol)
can be too concentrated to measure
Make a second dilution of the solutions (again a
1:1 aqueous dilution)
28A(ii) Sepharose beads visible in eluate SEC column has not been prepared
correctly
Prepare a new SEC column. Ensure that the
Nylon-net ﬁlter is placed in the middle of the
syringe (pre-wetting of the ﬁlter may help). Gently
ﬁll the syringe with Sepharose beads
29A–G Final sample of blank BEV separation
is not ‘negative’ in at least one of the
BEV-characterization techniques
Contamination occurred during the
protocol performance
Identify the step at which the contamination took
place and replace the contaminated buffers or
reagents with an endotoxin-free and sterile
alternative. The source of contamination can be
varied, from endotoxin-containing reagents to
non-sterile equipment
Table continued
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Timing
Step 1, sample collection: 5 min
Steps 2–7, sample preparation: 1 h 10 min
Steps 8–15, crude extract preparation: 1 h 30 min
Steps 16–27, BEV separation: 20 h
Step 28A, BEV recovery—SEC: 30 min
Step 28B, BEV recovery—ultracentrifugation: 3 h 30 min
Step 29A, BEV characterization—NTA: 10 min per sample
Step 29B, BEV characterization—TEM: 1 h per sample
Step 29C, BEV characterization—Western blotting: 20 h
Step 29D, BEV characterization—LPS activity measurements: 2 h
Step 29E, BEV characterization—TLR2/TLR4 activity measurements: 18 h
Step 29F, BEV characterization—PBMC stimulation experiments: 1 d 4 h
Step 29G, BEV characterization—proteomic analysis: 24 h
Box 2, protocol modiﬁcation for BEV analysis of blood samples: 72 h
Box 4, protocol modiﬁcation for BEV separation from an EcN bacterial cell culture: 48 h
Anticipated results
We demonstrated the ability of orthogonal biophysical separation and biochemical characterization
to analyze BEVs in human body ﬂuids.
Size-based separation of large-volume resuspended stool samples by low-speed centrifugation and
ultraﬁltration results in depletion of bacteria, eukaryotic cell debris and soluble components that are
<10 kDa, such as proteins and LPS. Size-based separation of blood plasma by low-speed cen-
trifugation and SEC results in depletion of blood cells, HDLs, soluble proteins and LPS (Fig. 1). Size-
based separation reduces the complexity of body ﬂuids, resulting in a crude extract that enables
density-based separation. The unique buoyant nature of BEVs allows density separation from ﬁbers,
protein aggregates and EEVs in stool; and from VLDLs and LDLs, chylomicrons, protein aggregates
and EEVs in blood (Fig. 1). The unique higher density of BEVs separates them from lower-density
EEVs in stool (the majority coming from gut epithelial cells) and blood (the majority coming from
platelets)6,35.
The most sensitive characterization method, TEM or immuno-EM, reveals the ultrastructure of
BEVs and identiﬁes the presence of single and double bilayered BEVs (Figs. 3 and 4c). The obser-
vation of double bilayered BEVs suggests the presence of outer–inner membrane vesicles (OIMVs)
derived from Gram-negative bacteria. The biogenesis of OIMVs requires that the inner membrane
Table 1 (continued)
Step Problem Possible reason Solution
29A(ii) No/low number of particles is
trackable during NTA measurement
Sample is too diluted Repeat the NTA measurement on a less diluted
sample. The particle concentration should be
within the detection range of the device (e.g., for
the NanoSight LM10 instrument: 3 × 108 to 1 × 109
particles/ml)
NanoSight is not sensitive enough Increase the camera level before NTA measure-
ment. This level determines the brightness of the
image by using preset combinations of shutter
and gain. Be aware that background signals will
also be picked up more quickly.
29B(viii) High amount of contaminants visible Incomplete separation of contaminants
(e.g., ﬁbers and ﬂagella) from BEVs
In Step 28, perform SEC (option A) instead of
ultracentrifugation (option B; see Fig. 4c).
Optionally repeat option A several times, because
this may further increase the BEV purity
29D(iii),
29E(iii)
Duplicates do not have similar
absorbance values
Inaccurate pipetting Repeat the assay and pipette accurately (consider
the use of a multichannel pipette)
Standard curve is not linear (whether
or not using a logarithmic scale)
Inaccurate pipetting and/or improper
preparation of the standard solutions
Repeat the assay and pipette accurately (consider
the use of a multichannel pipette). Be sure the
standard solutions are thoroughly mixed
NATURE PROTOCOLS PROTOCOL
NATURE PROTOCOLS |www.nature.com/nprot 25
protrude into the periplasm, allowing cytoplasmic contents to enter the vesicle, which is eventually
pinched off from the cell surface together with a surrounding outer membrane7. These inner
membrane proteins and cytoplasmic proteins are identiﬁed by mass spectrometry–based proteomics.
The presence of chromosomal DNA in OIMVs derived from body ﬂuids needs further investigation.
The simultaneous presence of LPS-containing outer membrane vesicles (OMVs) or OIMVs and
LTA-containing cytoplasmic membrane vesicles (CMVs) is evidenced by endotoxin assays and
TLR2/4 reporter assays. These assays show intermediate sensitivity, with the LAL assay being the
most sensitive (>105 Gram-negative BEVs) and the TLR2 reporter assay being the least sensitive
(>108 stool-derived BEVs; Fig. 3).
Starting from fresh stool samples, an overall high yield of BEVs can be expected. In our experience,
a minimal amount of 2.5 × 1011 BEVs per gram of wet stool (BSS category 3 or 4) is obtained if no
saturation of the stool sample in PBS occurred in Step 3 of the Procedure (Fig. 4b). For blood plasma
from patients with intestinal barrier dysfunction (IBD patients), an overall yield slightly lower than
106 BEVs/ml of plasma is obtained. Low-yield BEV samples are especially prone to misinterpretation
because of potential contamination derived from laboratory reagents and environments; such samples
require appropriate negative and positive controls, as discussed in the ‘Experimental design’ section.
The recovery efﬁciencies of the orthogonal biophysical separation methods must be considered as
well, and we estimate that an efﬁciency of 30% is achieved when using a combination of SEC and
density-gradient centrifugation24. However, a recovery efﬁciency of only 5% is obtained when
ultracentrifugation is performed in Step 28.
Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary
linked to this article.
Data availability
The data that support the ﬁndings of this study are available from the corresponding author upon
reasonable request.
Code availability
The computer code used for the robot-assisted steps of the protocol (Steps 20A and 27A) is available
from the corresponding author upon reasonable request.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Because this is a protocol, its purpose is purely didactic and thus no comparison of experimental groups was performed.
Data exclusions As this is a protocol format, not all the data from the original key publication is included in this study. 
Replication The protocol itself is replicated numerous times by different researchers.
Randomization During both separation and characterization of the bacterial extracellular vesicles, every sample is randomised.
Blinding This was not necessary for this protocol.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
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Materials & experimental systems
n/a Involved in the study
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Clinical data
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Antibodies
Antibodies used E. coli LPS antibody (2D7/1, Abcam, Cambridge, UK, cat. no. ab35654); OmpA antibody (Antibody Research Corporation, 
Missouri, USA, cat. no. 111120) 
Validation E. coli LPS antibody: according to the manufacturer it is suitable for: IHC-Fr, ICC/IF, IHC-P, IP, ELISA, WB and reacts with 
Escherichia coli. We also tested and validated the antibody for immuno EM on E. coli derived extracellular vesicles. OmpA 
antibody: according to the manufacturer is is suitable for: ELISA, WB and neutralization and reacts with E. coli and other gram 
negative bacteria (which we also observed by the cross-specificity of the OmpA antibody with different forms of outer 
membrane proteins present in the heterogeneous stool bacterial extracelular vesicle fractions during WB). We also tested and 
validated the antibody for immuno EM on E. coli derived extracellular vesicles. 
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) HEK-Blue-hTLR2 reporter cell line (InvivoGen, Toulouse, France, cat. no. hkb-htlr2); HEK-Blue-hTLR4 reporter cell line 
(InvivoGen, Toulouse, France, cat. no. hkb-htlr4)
Authentication Cell lines were authenticated by commercial provider
Mycoplasma contamination All cell lines tested negative for Mycoplasma contamination
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell line is used in this study
Human research participants
Policy information about studies involving human research participants
Population characteristics The human research participants in the supporting primary research paper were age- and sex matched (patients versus healthy 
volunteers). Baseline clinical characteristics of all the participants were recorded.
Recruitment Participants were randomly recruited to the study (of the supporting primary research paper). No (selection) bias is present.
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